LABCORP HOLDINGS INC. vs VERACYTE, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
The margin ladder inverts the size ladder: Veracyte, at $5B, earns a 72.7% gross margin and 16.3% operating on specialized genomic tests, while Labcorp, at $23B, earns 28.7% gross and 10.8% operating running the ordinary blood panels of American medicine. Specialization keeps more of every dollar; scale collects far more dollars. The multiples price the margin structure, 56 times Veracyte's earnings against 24.1 for Labcorp, and the cash flows price the scale, 6.2% yield at Labcorp against 3.2%. Veracyte holds a 9.3 current ratio and no debt; Labcorp carries a working 0.73 turns and pays a dividend. The boutique and the utility, each excellent at its own game, priced accordingly.
Comparison updated 2026-07-10.
| Metric | LH | VCYT |
|---|---|---|
| Price | $271.48 | $60.46 |
| Market cap | $22.5B | $4.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Mature | Growth |
| Implied growth (priced in) | -1.3% | — |
| P/E | 24.1 | 56.0 |
| P/B | 2.58 | 3.66 |
| P/S | 1.59 | 9.07 |
| EV/EBITDA | 17.3 | 56.1 |
| Revenue growth | +7.4% | +16.9% |
| Gross margin | 28.7% | 72.7% |
| Operating margin | 10.8% | 16.3% |
| Net margin | 6.7% | 16.3% |
| Return on equity | 10.8% | 6.5% |
| Return on assets | 4.9% | 6.1% |
| Return on invested capital | 7.5% | 5.5% |
| FCF yield | 6.2% | 3.2% |
| Dividend yield | 1.1% | — |
| Debt / equity | 0.73 | 0.00 |
| Current ratio | 1.73 | 9.31 |
| Altman Z (solvency) | 2.88 | 6.48 |
| Piotroski F (quality) | 4 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.